Research programme: cancer vaccines - Immunomic Therapeutics

Drug Profile

Research programme: cancer vaccines - Immunomic Therapeutics

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomic Therapeutics
  • Class Antineoplastics; Cancer vaccines; Cytomegalovirus vaccines; Dendritic cell vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 May 2017 Immunomic Therapeutics has patent protection for cytomegalovirus-targeting cancer vaccines licensed from Annias Therapeutics
  • 15 May 2017 Early research in Cancer in USA (Parenteral)
  • 15 May 2017 Immunomic Therapeutics in-licenses cytomegalovirus immunotherapy platform from Annias Immunotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top